June 13, 2020 by Chain Drug Review
COVID-19, Dr. Reddy's Laboratories, Gilead Sciences, Remdesivir
Pharmacy, Supplier News
PRINCETON, N.J.— Dr. Reddy’s announced that it has entered into a non-exclusive Licensing Agreement with Gilead Sciences that will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for COVID-19, in 127 countries including India. Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of this
May 8, 2020 by Chain Drug Review
Remdesivir, Senators Edward J. Markey (D-Mass.) and Elizabeth Warren (D-Mass.) and Congresswoman Ayanna Pressley
Leading Headlines, Pharmacy
WASHINGTON – Senators Edward J. Markey (D, Mass.) and Elizabeth Warren (D, Mass.) and Congresswoman Ayanna Pressley (MA-07) sent a letter on Friday calling on Vice President Mike Pence and the Secretary of Health and Human Services to immediately explain how the federal government is distributing remdesivir, a drug recently approved to treat COVID-19. Reports
May 4, 2020 by Chain Drug Review
Alex Azar, COVID-19, FDA, Remdesivir
Leading Headlines, Pharmacy
WASHINGTON — On Friday, the U.S. Food and Drug Administration issued an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. While there is limited information known about the safety and effectiveness of using remdesivir to treat people in the
April 30, 2020 by Chain Drug Review
COVID-19, National Institutes of Health (NIH), Remdesivir
Leading Headlines, Pharmacy
BETHESDA, Md.— Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized, controlled trial involving 1063 patients, which began on February 21. The trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by the National Institute
March 24, 2020 by Chain Drug Review
2019 Novel Coronavirus (COVID-19), Gilead Sciences, Remdesivir
Leading Headlines, Pharmacy
FOSTER CITY, Calif. — Gilead Sciences has temporarily stopped granting patients access to Remdesivir, its experimental drug against the novel coronavirus, citing “overwhelming demand,” the company stated this week. Gilead Sciences said in a statement that it is focused on processing previously approved requests, and that it is developing a new system that it says